Objectives: Non-small cell lung cancer (NSCLC) is a common cancer with a poor prognosis. The aim of this study was to screen Finnish NSCLC tumor samples for common cancer-related mutations by targeted next generation sequencing and to determine their concurrences and associations with clinical features. Materials and methods: Sequencing libraries were prepared from DNA isolated from formalin-fixed, paraffin-embedded tumor material of 425 patients using the AmpliSeq Colon and Lung panel covering mutational hot spot regions of 22 cancer genes. Sequencing was performed with the Ion Torrent Personal Genome Machine (PGM). Results: Data analysis of the hot spot mutations revealed mutations in 77% of the patients, with 7% having 3 or more mutations reported in the Catalogue of Somatic Mutations in Cancer (COSMIC) database. Two of the most frequently mutated genes were TP53 (46%) and KRAS (25%). KRAS codon 12 mutations were the most recurrently occurring mutations. EGFR mutations were significantly associated with adenocarcinoma, female gender and never/light-smoking history; CTNNB1 mutations with light ex-smokers, PIK3CA and TP53 mutations with squamous cell carcinoma, and KRAS with adenocarcinoma. TP53 mutations were most prevalent in current smokers and ERBB2, ERBB4, PIK3CA, NRAS, NOTCH1, FBWX7, PTEN and STK11 mutations occurred exclusively in a group of ever-smokers, however the association was not statistically significant. No mutation was found that associated with asbestos exposure. Conclusion: Finnish NSCLC patients have a similar mutation profile as other Western patients, however with a higher frequency of BRAF mutations but a lower frequency of STK11 and ERBB2 mutations. Moreover, TP53 mutations occurred frequently with other gene mutations, most commonly with KRAS, MET, EGFR and PIK3CA mutations.
Introduction
Non-small cell lung cancer (NSCLC) is the most common group of lung cancers with high mortality rates worldwide. In Finland, with a population of 5.5 million, approximately 2500 new cases of lung cancer are diagnosed annually [1] . Lung tumors, even of same histological subtype, can differ widely at the molecular level in their gene expression patterns, epigenetic changes, copy number alterations and mutations. Several of these genetic markers can be displayed simultaneously and influence the prognosis and treatment outcome [2] . Patients with activated EGFR or ALK oncogenes benefit from the targeted therapies, such as afatinib, erlotinib and gefitinib for EGFR, and crizotinib for ALK fusion [3] . Many NSCLC patients also harbor other molecular alterations, such as MET amplification or KRAS mutations, which might influence the efficacy of a targeted treatment, leading to primary or secondary resistance [4, 5] . Thus, it is important to investigate these concurrences of genetic markers in tumors, since they could reveal clinically important variants and/or serve as predictive and prognostic markers.
Ethnicity plays a role in the prevalence of some genetic markers [6] . Due to the genetic isolation of the Finnish population, we have examined these markers in a Finnish patient cohort. We used targeted next generation sequencing to determine mutations in hot spot regions, i.e. those reported in the Catalogue of Somatic Muta- tions in Cancer (COSMIC) database [7] , 22 lung cancer associated genes in 442 tumor samples of Finnish NSCLC patients.
Materials and methods

Tumor samples
We collected 442 formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens from NSCLC patients, of these, 425 patient samples were sequenced successfully. Tumor samples were obtained during radical lung cancer surgery in the Hospital District of Helsinki and Uusimaa (HUS), Finland, during 2006-2014. The majority of the samples were material removed during the surgery of the cancer (411 cases) with the remaining 14 obtained by core or fine needle biopsies. All samples were collected before any treatments. The ALK fusion status was tested by immunohistochemistry (IHC) and confirmed by fluorescence in situ hybridization (FISH) in 362 cases [8] . EGFR status, as tested by a real-time PCR kit, was known for 368 samples, due to partly overlapping material with our previous study [9] .
Histological subtypes and tumor cell contents of the samples were confirmed by a pulmonary pathologist. Tumor cell content was a minimum of 20% in 91% of the samples, and only eight samples had tumor content less than 10% (overall range 5-90%). The majority of the tumors were adenocarcinoma (67%) or squamous cell carcinoma (21%). The detailed histological subtyping and other clinical characteristics of the patients are presented in Table 1 . Patients were grouped according to their smoking status as: neversmokers, ex-light smokers (<20 years and ceased >10 years ago), ex-medium smokers (>20 years and ceased), and current smokers (>20 years and ongoing). Asbestos exposure was evaluated by interview about the occupational history and/or fiber count by SEM on normal lung tissue [10] . Samples with more than 2.0 million asbestos fibers per gram of dried lung tissue, were grouped as asbestos-exposed, and those with less than 1.0 million fibers per gram of dried lung tissue were considered as non-exposed. Samples not fulfilling these criteria were considered as uncertain with regard to asbestos exposure. Survival outcome data were cut-off on March 5, 2016. The mean time period of follow-up was 43.7 months (range 1-141 months). The study was approved by the institutional ethics committee.
DNA extraction
DNA was extracted by the QIAamp DNA Mini Kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer's protocol with some changes, as described [11] . DNA samples were quantified with the Qubit ® 2.0 fluorometer (Thermo Fisher Scientific) using the Qubit ® dsDNA BR assay kit (Thermo Fisher Scientific).
Next generation sequencing
Sequencing libraries were prepared from 10 ng of DNA samples using the Ion AmpliSeq TM Colon and Lung Cancer Panel together with the Ion AmpliSeq TM Library Preparation Kit (Thermo Fisher Scientific) according to the manufacturer's guidelines. The Colon and Lung Cancer panel contains 504 mutational hot spots (totaling 14.6 kb) of 22 genes : AKT1, ALK, BRAF, CTNNB1, DDR2, EGFR,  ERBB2, ERBB4, FBXW7, FGFR1, FGFR2, FGFR3, KRAS, MAP2K1, MET,  NOTCH1, NRAS, PIK3CA, PTEN, 
Data analysis
The raw sequencing data were aligned to the hg19 and analyzed with TorrentSuite TM Software (v.4.0.2) (Thermo Fisher Scientific). Mutations were detected using the Variant Caller plug-in (v4.0-r76860) (Thermo Fisher Scientific) using default settings, i.e. a quality score of minimum 6, relative read quality of minimum 6.5, coverage of minimum 6 for SNP/COSMIC variant and 15 for indel, and strand bias maximum of 95% for SNP/COSMIC variant and 90% for indel. Further data filtering was conducted to include only those variants that had a frequency of variant reads with a minimum of 3%, and an average phred quality score minimum of 15 for previously known COSMIC mutations and a minimum of 20 for novel variants.
The coverage analysis was performed using the Coverage Analysis plug-in (v4.0-r77897) (Thermo Fisher Scientific). Statistical analyses were performed with IBM SPSS Statistics version 22 (IBM Corp., Armonk, NY). Fisher's exact test was used to compare mutation positive and negative groups with categorical features. Independent t-test was used for comparison of mutation statuses and age. Two-sided p values < 0.05 were considered statistically significant.
Results
Ion Torrent PGM sequencing was performed on 442 samples, with the results from 425 NSCLC samples being successfully completed and presented here. The samples not included were mainly those with low sequencing coverage/libraries. The samples included in the final sequencing analysis had an average coverage of 1623, (range 146-4137) and a uniformity of coverage of 98.7% (range 87.7-100%). Only non-synonymous variants were included.
The majority (77%) of the tumor samples had one or more mutations listed in the COSMIC database (Fig. 1) ; 46% carried one mutation, 25% two mutations, 4% three mutations, 2% four mutations, two cases had five mutations, one case displayed seven mutations and one case had as many as 15 mutations. Mutation frequencies differed between ADC and non-ADC histologies, as represented in Fig. 1 (b and c) . TP53 was the most frequently mutated gene, followed by KRAS (Fig. 2) . No COSMIC mutations were seen in the following genes included in the Colon and Lung Cancer panel: ALK, DDR2, FGFR1, FGFR2, MAP2K1 and SMAD4. However, non-synonymous novel mutations predicted as deleterious were detected in those genes (Supplemental File S1 and Fig. 2a ). The top most recurrent mutations seen in tumors are presented in Fig. 2b .
COSMIC mutations
The COSMIC mutations detected in the tumors are shown in Table 2 , and TP53 mutations in Supplemental File S2. TP53 was the most frequently mutated gene with 46% of the patients harboring one or more TP53 mutations. KRAS mutations were the second most common, with mutations in codons 12 and 13 being the most recurrent (25%). Two patients carried double Gly12Cys and Gly12Val KRAS mutations. The concurrencies of the different gene mutations are presented in Table 3 . KRAS mutations (codon 12/13) were seen together with many other gene mutations and also with EGFR mutations His870Tyr in one case and Leu858Arg + Ala871Thr + Gly735Ser in one other.
One sample was exceptional, having multiple mutations in many different genes that included KRAS Gly13Cys; EGFR Leu858Arg, Ala871Thr and Gly735Ser; BRAF Ser605Asn; CTNNB1 Pro44Ser; ERBB4 His618Tyr; PIK3CA Met1043Ile. This sample was from a 72 years old female, who was an ex-medium-smoker, nonexposed to asbestos and had a radically operated adenocarcinoma; she was still living 47 months after her operation.
EGFR mutations were detected in 8% of the samples. One of these was a triple mutant, as described above; there were three double EGFR mutants: Leu858Arg + Asp761Tyr, Leu858Arg + Arg776Cys, and Gly719Ser + Ser768Ile. Clinically relevant exon 19 deletions, exon 20 insertions, Leu858Arg or Gly719Ala were seen together with TP53 mutations in 17 patients. Moreover, Leu858Arg was detected simultaneously with MET Asn375Ser in four cases, and Gly719Ala with CTNNB1 Ser37Phe in one case.
BRAF mutations were found in 5.6%, but only four cases harbored the Val600Glu mutation (0.1%) and no concurrent mutations were detected in these cases. Other mutations were detected in residues 466, 469 (exon 11), 586, 594, 597, 601 and 605 (exon 15). Two patients with BRAF mutations (Ser605Asn or Gly466Val) also harbored activating KRAS (codon 12 or 13) mutations. TP53 mutations were the most frequent concurrent gene mutations, occurring together with nearly all mutated genes (except for NRAS or FBWX7). Approximately 50% of the EGFR and BRAF and 35% of KRAS mutation positive samples also harbored a TP53 mutation. MET mutations were detected in 33% of PIK3CA and 17% of RAS mutants.
Novel variants
There were 195 novel mutations that led to an amino acid change (including missense, nonsense and indels) which have not been reported in dbSNP (Build 146). The novel variants were analyzed in-silico with SIFT [12] and PROVEAN [13] tools to check the effect of the variants on protein function. Almost half (93) of the 195 novel missense variants were predicted to be deleterious/damaging by both SIFT and PROVEAN. Eleven variants were nonsense variants and 20 were in-frame/frameshift variations, thus also potentially damaging. All of the novel variants resulting in amino acid change are listed in Supplemental File S1 and all 124 deleterious missense, nonsense and in-frame/frameshift mutations in different genes are shown in Fig. 2a . Two novel exon 19 deletions of EGFR, one 11 bp insertion/frameshift variation of ERBB2 and one 21 bp in-frame deletion in TP53 were among the novel variants.
COSMIC mutations and their association with clinical characteristics
Statistically significant associations were seen between EGFR mutations and adenocarcinoma histology (p = 0.037). Similarly, never and light ex-smokers (p < 0.001) and female patients (p < 0.001) harbored the majority of the EGFR mutations. Moreover, PIK3CA (p = 0.016) and TP53 (p < 0.001) mutations were most prevalent in squamous cell carcinoma and KRAS in adenocarcinoma (p < 0.001). CTNNB1 mutations tended to be associated with a group of light ex-smokers (p = 0.011) ( Table 4) .
Patient survival
Survival data were available for 420 patients with a median follow-up of 43.7 months. Due to a short follow-up time, KaplanMeier analyses were not applicable. As an observational result, 53% (216/406) of the operated patients were alive; a total of 165 lung cancer-related death events occurred. Two out of 14 nonoperated patients (14%) were alive at the end of follow-up. In adeno-, adenosquamous, squamous cell and large cell carcinomas, there were cancer related deaths observed in 34%, 46%, 28% and 62%, respectively. Lung cancer related death occurred in 53% (16/30) of the patients with more than three COSMIC mutations, whereas the proportions in other patients were: two mutations −20% (21/104), one mutation −37% (70/191) and no mutations −36% (34/95).
Discussion
In present study, the most frequently mutated genes were, in descending order: TP53, KRAS, MET, EGFR, BRAF, PIK3CA and CTNNB1. In other genes; STK11, PTEN, ERBB2, NOTCH1, ERBB4, FBWX7, FGFR3, AKT1 and NRAS, COSMIC mutations were present in less than 2% of the patients. A majority of EGFR mutation statuses (n = 368) were validated by golden standard PCR, results of which were compared in more detail in our previous study [14] . Briefly, a great concordance of 99.7% was obtained. Thus, we believe the results of Ion Torrent PGM NGS are trustful. Moreover, we were able to detect the known EGFR and KRAS mutations with good quality valued even in those samples with lower tumor content (<20%). However, we might have missed some mutations in few (n = 8) samples with tumor content less than 10%. Unfortunately, normal material was not available for testing the somatic nature of mutations, thus, some of the mutations reported might be of germ line origin, although they have been reported in COSMIC.
The frequency of activating EGFR mutations (7%; COSMIC 8%) was similar or slightly higher than that in other studies examining Western or Central European NSCLC patients (4.9-13.8%) [15] [16] [17] [18] [19] . KRAS mutations were the second most common mutations after TP53. ADCs were mutated at a frequency of 35%, while 26% of all b MET mutations detected in this study were Asn375Ser and Thr1010Ile, which are described in NCBI dbSNP as germline, and in COSMIC database being confirmed as somatic. (30) 1 (3) 1 (2) 0.4 (1) 16 (46) 00 3 (7) 35 (100) 0 7 (20) 4 (10) 1 (2) 0.4 (1) 1 (3) 2 (7) 37 ( (10) 2 (5) 1 (2) 1 (2) 2 (5) 3 (7) 45 (108) Abbreviations: ADC, adenocarcinoma; ADSQ, adenosquamous carcinoma; CS, current smoker; LCC, large cell carcinoma; LS, light ex-smoker; MS, medium ex-smoker; NS, never-smoker; SCC, squamous cell carcinoma. a No statistical assessment, because mutation occurred in a case with a missing value.
NSCLC cases carried a KRAS mutation, which is in concordance with the previous studies on European NSCLC patients (15-33%) [15, 17] . Activating KRAS, EGFR, BRAF mutations and ALK fusions have been postulated to be mutually exclusive [6] , and this proposal is confirmed in our study. Only one case, carrying 15 different mutations in seven genes, harbored both activating KRAS and EGFR mutations. Two cases harbored concurrent KRAS and BRAF (Gly466Val and Ser605Asn) mutations, that have been previously reported [20, 21] . Even though the frequency of most mutations was similar as in other studies on Caucasian patients, there were two genes, BRAF and MET that did differ. The proportion of BRAF mutations was 6%, which is higher than reported in a recent meta-analysis (3%, range 0.9-8.9%) [21] , or in the studies examining European patients (2.1-3.5%) [21, 23, 24] . The highest frequency of 8.9% in the metaanalysis can be explained mainly due to selection of only EGFR, KRAS, PIK3CA, HER2 and ALK wild-type patients in that study [25] . Although Val600Glu mutations have been reported to account for approximately half of the BRAF mutations in NSCLC patients [21] , here the proportion of Val600Glu mutations was much lower (4/24, 17%), and the Val600Glu mutation frequency (0.9%) was lower than that reported previously, such as in Norwegian patients (1.7%) [26] . BRAF mutations other than Val600Glu seem to be more prevalent in Finnish NSCLC patients. The clinical significance of these mutations still remains partly unresolved, although some of them seem to be kinase activating and thus might play an important role in driving tumorigenesis [27] [28] [29] .
MET mutations were seen in 16% of ADCs, which is more than double than reported elsewhere (7%) [30] . Both MET mutations detected in this study, Asn375Ser and Thr1010Ile, have been reported as germline in NCBI dbSNP and as somatic in COSMIC. The frequency of Thr1010Ile was three time higher in our NSCLC patients than reported for the general Finnish population in 1000 Human Genomes (NCBI 1000 Genomes Browser): 6.1% (26/425) vs. 2.0%, but for Asn375Ser very similar: 9.4% (40/425) vs. 11%. Unfortunately, because of the lack of normal tissue material, we were unable to confirm their somatic/germline origin.
In this study, the frequency of hot spot mutations in HER2 (0.7% vs. 1.6-6%) [6, [30] [31] [32] [33] and STK11 (1.7% vs. 16-19%) [6, 34, 35] was lower than described elsewhere. STK11 mutations have been reported to be associated with Caucasian ethnicity [6, 33] . The lower frequency in our study could be partly explained by the fact that our NGS panel covered only the mutation hotspot regions of the genes [34, 35] . However, two out of eight STK11 mutations were seen together with KRAS, and five with TP53. A similar trend of concurrent STK11 + TP53 and KRAS + STK11 was reported in a recent meta-analysis on Western ADCs [6] .
HER2 mutations are believed to be more prevalent in adenocarcinoma, and never-smokers [6, 32, 36] . All three hot spot mutations detected in this study occurred in adenocarcinoma, but in eversmokers (two medium ex-smokers and one current smoker). In addition to hot spot mutations, six novel mutations were detected, which increases HER2 mutation frequency to 2%, which is more similar to previous reports [6, 36] .
In our patients, the frequency of TP53 mutations was as high as 46.4%. The frequency of TP53 mutations has been reported to be around 40% (17-68%) among smokers and 21% (0-40%) among non-smokers in a meta-analysis of TP53 mutations in lung cancer patients [37] . We found clear evidence of concurrence of mutated TP53 with many other mutant genes, especially with EGFR and KRAS, in our patients. Nearly half of the EGFR and BRAF mutants and 35% of the KRAS/NRAS mutants harbored one or more concomitant TP53 mutations. Earlier reports have described similar concurrent TP53 mutations with EGFR, KRAS and STK11 mutations although at much lower frequencies (less than 10%) [6] . The high frequency of mutated TP53 found here might be one reason for its higher concurrence with other gene mutations.
We also evaluated the association of smoking history, asbestos exposure, histological subtype, age, gender and survival with mutation status. EGFR mutations were associated with female gender, never-smokers and adenocarcinoma subtype as reported previously [6, 31, 38] . CTNNB1 mutations were significantly associated with ex-light-smokers, and as far as we are aware, this association has not been reported previously. COSMIC mutations in ERBB2, ERBB4, PIK3CA, NRAS, NOTCH1, FBWX7, PTEN and STK11 occurred exclusively in ever-smokers, but without statistical significance. TP53 mutations were most prevalent in the current smokers, but similarly, statistical significance was not reached (p = 0.135). In a recent meta-analysis, it was concluded that smokers have higher risk for p53 mutations [37] .
When evaluating the association of mutation status and asbestos-exposure, EGFR mutations were seen more frequently in the non-exposed group (9% vs. 0%, p = 0.146) and TP53 mutations in the asbestos-exposed group (62% vs. 46%, p = 0.118). However, in our previous study, EGFR mutations were seen in both asbestosexposed (interview only) and non-exposed groups (11% vs. 10%, p = 0.498) [9] . The frequency of MET and KRAS mutations was similar in both non-exposed and exposed groups, 17% vs. 10% and 25% vs. 21%, respectively. This is concordant with our previous findings that KRAS mutations are not associated with asbestos exposure [39] . However, we were unable to find any mutations significantly associated with asbestos exposure due to the small number of asbestos-exposed patients and the high proportion of uncertain/only partial information regarding asbestos-exposure.
PIK3CA and TP53 mutations were associated with SCCs, which is concordant with previous studies [30, 40, 41] . In agreement with a meta-analysis [22] , BRAF mutations showed no significant association with histology, gender or smoking status. However, similarly to the meta-analysis, BRAF mutations were more likely to occur in females (8% vs. 4% in male) and never-smokers (11% vs. 5% in ever-smokers).
The majority of our patients were in the early operable stage of disease and their follow-up time was short, therefore, no clear conclusions can be drawn regarding the association between mutations and survival. TP53 [42] [43] [44] and KRAS mutations [45] , and multiple mutations [46] , have been reported to predict poorer cancer-related overall survival. However, a similar trend was observed, i.e. 53% of the patients with 3 or more hot spot mutations, died of lung cancer in comparison to 32% of the patients with less than 3 mutations.
Conclusions
This hot spot mutation screening of a large Finnish NSCLC cohort suggests that although mutation profiles do not differ essentially from other Western patients, mutations in BRAF are seen more frequently, and those in STK11 and ERBB2 less often in Finnish NSCLC patients. Mutations in TP53 were the most frequent (46%) and they tended to occur along with EGFR and KRAS mutations. As a novel finding, we observed CTNNB1 mutations to be significantly associated with ex-light smokers.
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